Diligence memo · auto-generated · as of July 2, 2026
Haplotype Labs, Inc.
Haplotype Labs, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Haplotype Labs, Inc. operates in AI / ML, based in ORINDA, CA, USA; Remote. Personalized prevention using genetics and AI
Sub-sector tags: Diagnostics, Healthcare, ai/ml, saas.
Capital & rounds (filed)filed
Haplotype Labs, Inc. has raised $1.1M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.1M on 2024-03-29.
Most recent recorded round closed around 2024-03-29.
Valuation (modeled)modeled
Provath models Haplotype Labs, Inc. at approximately $7.0M (range $970K–$20M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.39× the median modeled value of Seed AI / ML companies in 2022–2024 (73 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.3 yr ago; this sector typically re-raises about every 11 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 72% of AI / ML peers (2067 compared).
Modeled value ranks above 73% of those peers.
Closest niche peers: MD.ai, Inc., Edge AI Solutions Inc., Operative Intelligence Holdings Inc., Bookend AI Inc., Globus AI, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.